Context Therapeutics Inc. (CNTX)
| Market Cap | 22.10M -82.5% |
| Revenue (ttm) | n/a |
| Net Income | -45.96M |
| EPS | -0.48 |
| Shares Out | 91.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,338,682 |
| Open | 0.2520 |
| Previous Close | 0.2556 |
| Day's Range | 0.2358 - 0.2729 |
| 52-Week Range | 0.2358 - 3.6200 |
| Beta | 1.72 |
| Analysts | Buy |
| Price Target | 4.03 (+1,575.68%) |
| Est. Earnings | Nov 4, 2026 |
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Penn... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CNTX stock is "Buy." The 12-month stock price target is $4.03, which is an increase of 1,575.68% from the latest price.
News
Context Therapeutics doses first patient in CT-202 trial
Context Therapeutics (CNTX) announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 TCE bispecific antibody.
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers...
Context downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital analyst Charles Zhu downgraded Context Therapeutics (CNTX) to Market Perform from Outperform.
Context Therapeutics price target lowered to $3 from $4 at Citizens
Citizens analyst Silvan Turkcan lowered the firm’s price target on Context Therapeutics (CNTX) to $3 from $4 and keeps an Outperform rating on the shares following the company’s Q2 earnings…
Context Therapeutics reports Q2 EPS (15c), consensus (9c)
“During the second quarter, we advanced our pipeline and reported interim Phase 1a data from CTIM-76 in a limited number of heavily pretreated patients with platinum-resistant ovarian cancer receiving...
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund ope...
Context Therapeutics Quarterly report: Q2 2026
Context Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Context Therapeutics Earnings release: Q2 2026
Context Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Context Therapeutics Slides: Corporate presentation
Context Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific a...
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bisp...
Context Therapeutics price target lowered to $4 from $8 at Maxim
Maxim analyst Jason McCarthy lowered the firm’s price target on Context Therapeutics (CNTX) to $4 from $8 but keeps a Buy rating on the shares. The firm cites the company…
Context Therapeutics selloff brings buying opportunity, says JonesResearch
JonesResearch views today’s selloff in shares of Context Therapeutics (CNTX) as a buying opportunity. Context’s Phase I study update of CTIM-76 in CLDN6+ solid tumors is “encouraging,” says the firm,…
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar tells investors in a research note that Context Therapeutics (CNTX)’ initial CTIM-76 data in heavily pretreated CLDN6-positive cancers, particularly platinum-resis...
Context Therapeutics Transcript: Study result
Interim phase I data for CTIM-76 in platinum-resistant ovarian cancer show a 29% response rate and favorable safety, with low-grade CRS and promising durability in heavily pretreated patients. Q3-week dosing is expected to further optimize efficacy and tolerability.
Context Therapeutics Press release: Study result
Context Therapeutics issued a press release on June 15, 2026, disclosing material business information to investors.
Context Therapeutics Slides: Study result
Context Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
Context Therapeutics (CNTX) announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer....
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy
Context Therapeutics Slides: Corporate presentation
Context Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 13, 2026.
Context Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three T-cell engager programs are advancing for solid tumors, with the lead Claudin 6 candidate showing promising early efficacy and safety in ovarian cancer. Combination strategies with ADCs and PD-1/VEGF inhibitors are planned, and key data updates are expected in the coming months.
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific an...
Context Therapeutics enters license agreement amendment with BioAtla
Context Therapeutics (CNTX) announced the amendment of the company’s exclusive license agreement, dated September 23, 2024, with BioAtla (BCAB). The amendment removes all future milestone and royalty ...
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
Context Therapeutics reports Q1 EPS (9c), consensus (12c)
Cash and cash equivalents were $54.5M at March 31, 2026, compared to $66.0M at December 31, 2025. The company expects its cash and cash equivalents will be sufficient to fund…